每经AI快讯，1月4日，兴齐眼药(300573.SZ)公告称，公司收到国家药品监督管理局核准签发的硫酸阿 托品滴眼液《药品补充申请批准通知书》。该药品适用于延缓球镜度数为-1.00D至-4.00D（散光 ≤1.50D、屈光参差≤1.50D）的6至12岁儿童的近视进展。公司在已上市硫酸阿托品滴眼液基础上增加两 个产品规格，分别为0.02%（0.4ml：0.08mg）和0.04%（0.4ml：0.16mg）。研究结果显示，0.02%和 0.04%阿托品滴眼液与安慰剂相比，均能有效延缓儿童近视进展，且总体安全性良好。由于医药产品市 场销售情况可能受多种因素影响，存在不确定性，敬请投资者谨慎决策，注意投资风险。 （文章来源：每日经济新闻） ...

兴齐眼药1月4日公告，公司收到国家药品监督管理局核准签发的硫酸阿托品滴眼液《药品补充申请批准 通知书》。该药品的适应症为：本品用于延缓球镜度数为-1.00D至-4.00D（ 散光 ≤1.50 D 、 屈光参差 ≤1.50 D ）的6至12岁儿童的近视进展。本次补充申请是在公司已上市硫酸阿托品滴眼液基础上增加两 个产品规格（1）0.02%（0.4ml:0.08mg）、（2）0.04%（0.4ml:0.16mg）。 ...

证券代码：300573 证券简称：兴齐眼药 公告编号：2026-001 沈阳兴齐眼药股份有限公司 关于获得药品注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 今日，沈阳兴齐眼药股份有限公司（以下简称"公司"）收到国家药品监督 管理局（以下简称"国家药监局"）核准签发的硫酸阿托品滴眼液《药品补充申 请批准通知书》。现将有关事宜公告如下： 一、药品基本情况 药品通用名称：硫酸阿托品滴眼液 英文名/拉丁名：Atropine Sulfate Eye Drops 注册分类：化学药品 审批结论：根据《中华人民共和国药品管理法》及相关规定，经审查，2024 年 10 月 29 日受理的硫酸阿托品滴眼液符合药品注册有关要求，同意批准本次补 充申请。 上市许可持有人、生产企业：沈阳兴齐眼药股份有限公司 药品批准文号：（1）国药准字 H20258301（2）国药准字 H20258302 药品批准文号有效期：至 2029 年 03 月 04 日 二、药品的其他相关情况 公司硫酸阿托品滴眼液的研发代码为 SQ-729，适应症为：本品用于延缓球 镜度数为-1.00D 至 ...

兴齐眼药公告，公司收到国家药监局核准签发的硫酸阿托品滴眼液《药品补充申请批准通知书》。药品 规格为0.02%(0.4ml：0.08mg)和0.04%(0.4ml：0.16mg)，适应症为延缓6至12岁儿童近视进展。药品批准 文号有效期至2029年03月04日。 ...

Market Overview - The Shanghai Composite Index rose by 0.09% on December 31, with 15 industries experiencing gains, led by defense and military industry at 2.13% and media at 1.54% [1] - The communication and agriculture, forestry, animal husbandry, and fishery sectors saw the largest declines, down 1.35% and 1.10% respectively [1] - The pharmaceutical and biotechnology sector fell by 0.45% [1] Capital Flow Analysis - The main capital outflow from the two markets totaled 32.27 billion yuan, with 9 industries seeing net inflows [1] - The defense and military industry had the highest net inflow of 6.06 billion yuan, followed by the media sector with 4.45 billion yuan [1] - A total of 22 industries experienced net capital outflows, with the electronics sector leading at 11.20 billion yuan, followed by the power equipment sector at 7.25 billion yuan [1] Pharmaceutical and Biotechnology Sector - The pharmaceutical and biotechnology sector saw a net outflow of 3.54 billion yuan, with 178 of the 478 stocks in the sector rising and 276 falling, including one stock hitting the daily limit down [2] - The top three stocks with net inflows in this sector were Meinian Health (84.95 million yuan), Huaren Health (75.69 million yuan), and Xingqi Eye Medicine (64.86 million yuan) [2] - The stocks with the largest net outflows included WuXi AppTec (468.14 million yuan), Mindray Medical (321.35 million yuan), and Hefei China (276.65 million yuan) [3]

证券代码：300573 证券简称：兴齐眼药 公告编号：2025-068 沈阳兴齐眼药股份有限公司 关于公司药品生产许可证变更的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 法定代表人：刘继东 企业负责人：高峨 质量负责人：薛晓柏 生产负责人：许嘉宜 沈阳兴齐眼药股份有限公司（以下简称"公司"）于近日取得辽宁省药品监 督管理局下发的《药品生产许可证》。本次主要涉及住所（经营场所）的变更， 变更后的《药品生产许可证》信息具体内容如下： 企业名称：沈阳兴齐眼药股份有限公司 许可证编号：辽 20150024 社会信用代码：912101001179988209 分类码：AhBhCh 住所（经营场所）：辽宁省沈阳市浑南区新运河路 25 号 董事会 2025 年 12 月 29 日 质量受权人：薛晓柏 有效期至：2030 年 12 月 10 日 生产地址和生产范围：沈阳市浑南区泗水街 68 号：滴眼剂，眼用凝胶剂， 眼膏剂，吸入制剂，耳用制剂[滴耳剂（无菌）]，涂剂*** 以上变更不会对公司生产经营产生重大影响，敬请广大投资者理性投资，注 意投资风险。 特此公告。 ...

证券日报网讯12月25日，兴齐眼药（300573）发布公告称，为降低管理成本、优化资源配置，已完成对 全资子公司科启制药的注销登记，工商变更已办结。科启制药成立于2022年2月，注册资本3000万元， 主营药品生产与研发。注销后，公司合并报表范围调整，但预计不会对公司财务及经营成果产生实质性 影响，也不损害股东利益。 ...

证券代码：300573 证券简称：兴齐眼药 公告编号：2025-067 沈阳兴齐眼药股份有限公司 关于全资子公司完成注销登记的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 沈阳科启制药有限公司（以下简称"科启制药"）为沈阳兴齐眼药股份有限 公司（以下简称"公司"）全资子公司。为降低管理成本，优化资源配置，公司 决定注销科启制药。根据《中华人民共和国公司法》《公司章程》相关规定，本 次注销事项在公司经营层决策权限内，无需提交董事会审议。同时本次注销事项 不构成关联交易，亦不构成《上市公司重大资产重组管理办法》规定的重大资产 重组。具体情况如下： 一、注销主体基本情况： 1、统一社会信用代码：91210106MA7HYDPU00 2、名称：沈阳科启制药有限公司 3、类型：有限责任公司（法人独资） 4、法定代表人：刘继东 5、经营范围：许可项目：药品生产，药品研发，药品零售（依法须经批准 的项目，经相关部门批准后方可开展经营活动，具体经营项目以审批结果为准） 6、注册资本：人民币叁仟万元整 7、成立日期：2022 年 02 月 21 日 8、住所：辽宁省沈阳 ...

Core Insights - The article discusses the growing importance of consumer healthcare products in addressing chronic health issues like obesity, insomnia, hair loss, myopia, and low immunity, emphasizing the need for pharmaceutical companies to align products with consumer demands and establish effective sales channels [1] Group 1: Market Trends and Company Strategies - Pharmaceutical companies are increasingly entering the consumer healthcare sector, with notable examples including Novo Nordisk's semaglutide and Eli Lilly's tirzepatide, which have generated significant revenue [1] - Sanofi's product, Lybrel, is expected to become a star product in the Chinese market by 2025, showcasing the potential for online sales growth [1] - Three Life Pharmaceuticals' Mandi International is set to go public in Hong Kong, with its minoxidil hair loss treatment dominating the Chinese market, projecting revenue growth from 982 million to 1.455 billion yuan from 2022 to 2024, representing a compound annual growth rate of 21.7% [1] Group 2: Product Performance and Market Position - Mandi's hair loss treatment accounted for over 90% of its total revenue from 2022 to mid-2025, highlighting the substantial market for hair loss products in China [1] - Compared to service-oriented companies like Yonghe Medical, Mandi demonstrates superior profitability in the consumer healthcare sector, indicating that product-based companies can achieve higher margins [1] Group 3: Innovations in Consumer Healthcare - Eisai's Lybrel has gained traction due to its novel mechanism of action, which avoids the regulatory constraints of traditional sedative-hypnotics, and its partnership with JD Health enhances its market reach [2][3] - The dual orexin receptor antagonists (DORAs) used in Lybrel promote natural sleep by inhibiting the overactive orexin system, reducing dependency and side effects associated with traditional sleep medications [2] Group 4: Market Opportunities and Challenges - The consumer healthcare market in China has reached a trillion yuan scale, with early entrants gaining brand influence and market share, while new entrants face challenges in competing against established players [5] - There are still unmet needs in various segments such as osteoporosis, sports rehabilitation, and skin care, suggesting opportunities for new products in the consumer healthcare space [6]

Core Viewpoint - The article discusses the trend of public funds hiring managers with pharmaceutical backgrounds to enhance their portfolios, particularly in the context of a market correction in the innovative drug sector as the year-end approaches [1][2]. Group 1: Hiring Trends - Several non-pharmaceutical themed funds have recently announced the hiring of managers with pharmaceutical expertise, indicating a shift towards a more balanced investment strategy [2][3]. - The hiring of these managers is seen as a response to the need for diversified portfolio management amid increasing market volatility and sector rotation [5][6]. Group 2: Fund Examples - Silver华 Fund announced the hiring of Wu Ying, a manager with a strong pharmaceutical background, for its Silver华乐享生活 mixed fund, which previously focused heavily on semiconductor stocks [3][4]. - Similarly, Ping An Fund appointed Fang Junping, another pharmaceutical investment veteran, to co-manage its Ping An Balanced Selection mixed fund, which had a predominant focus on real estate stocks [4][5]. Group 3: Market Outlook - The hiring of pharmaceutical managers is driven by expectations of a sustained uptrend in the pharmaceutical sector, with a focus on the upcoming performance of Chinese pharmaceutical companies [7][8]. - Analysts predict that 2026 will be a pivotal year for innovative drugs, with potential for both earnings and valuation expansion, as many companies are expected to release significant clinical data [7][8].